Taysha Gene Therapies Retained Earnings (Accumulated Deficit) 2020-2024 | TSHA

Taysha Gene Therapies retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Taysha Gene Therapies Retained Earnings (Accumulated Deficit) 2020-2024 | TSHA

Taysha Gene Therapies retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
Dr Reddy's Laboratories (RDY)$11.9B
BridgeBio Pharma (BBIO)$4.4B
Bausch Health Cos (BHC)$2.9B
Amphastar Pharmaceuticals (AMPH)$2.2B
Supernus Pharmaceuticals (SUPN)$2B
Personalis (PSNL)$245M
Assembly Biosciences (ASMB)$96M
Sol-Gel Technologies (SLGL)$15M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M